TRACERx Reduced-representation bisulfite sequencing (RRBS)
RRBS data from TRACERx non-small cell lung cancer (NSCLC) tumours and matched normal adjacent tissue. TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC).
- 155 samples
- DAC: EGAC00001000632
- Technology: Illumina HiSeq 2500
TRACERx Non-small cell lung cancer
”The Francis Crick Institute allows access to published datasets upon written application and signature of a Data Access Agreement (DAA) to be provided. Applications require approval by the TRACERx Data Access Committee (DAC), who assess whether the proposed work is allowed given patient consent, as well as the scientific purpose. Requestors will be provided with a data access form upon contact with the TRACERx DAC.”
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |